Navigation Links
Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
Date:7/21/2011

opioids.

Life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl products to FENTORA.  Carefully consult the Initial Dosing Recommendations table. [See Dosage and Administration (2.1)]

When dispensing, do not substitute a FENTORA prescription for other fentanyl products.  Substantial differences exist in the pharmacokinetic profile of FENTORA compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl.  As a result of these differences, the substitution of FENTORA for any other fentanyl product may result in fatal overdose.  

Special care must be used when dosing FENTORA. If the breakthrough pain episode is not relieved after 30 minutes, patients may take ONLY one additional dose using the same strength and must wait at least 4 hours before taking another dose. [See Dosage and Administration (2.1)]

FENTORA contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.  FENTORA can be abused in a manner similar to other opioid agonists, legal or illicit.  This should be considered when prescribing or dispensing FENTORA in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.  Schedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.

Patients and their caregivers must be instructed that FENTORA contains a medicine in an amount which
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Shareholders Approve Acquisition by Teva
2. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
3. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
4. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
5. Cephalon Lodges Bidders Statement for A$167 Million Offer for ChemGenex Pharmaceuticals
6. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
7. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
8. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
9. Cephalon Wins FENTORA Patent Suit Against Watson
10. Cephalon Announces Definitive Agreement to Acquire Gemin X
11. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NEW YORK and KISSING, Germany ... manufacturer and distributor of a single use and computer-assisted ... Nachum (Homi) Shamir , a worldwide recognized medical device ... Mr. Shamir is a highly respected ... most recent assignment he served as President and Chief ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , SAN FRANCISCO, Nov. 4 VIA Pharmaceuticals, Inc. ... the development of compounds for the treatment of cardiovascular ... Senior Vice President Research & Development will present "VIA-3196, ... in the Abstract Oral Session on Novel Biological Mechanisms ...
... CVS Caremark (NYSE: CVS ) today announced ... SVP, Marketing for its pharmacy benefit management business. ... Jack Bruner, who is transitioning to the new role ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings twenty years ...
Cached Medicine Technology:VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 2VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 3VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 4Company Appoints New SVP, Marketing for PBM Business 2
(Date:7/30/2014)... San Francisco, California (PRWEB) July 30, 2014 ... reach USD 46.05 billion by 2020, according to a ... for minimally invasive procedures and the growing prevalence of ... market growth over the forecast period. In addition, the ... the rising market penetration of minimally invasive procedures in ...
(Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) into ... in Westchester County takes the best of everything. Leading ... corporate structure and protocols, and a staff that is ... Chief Financial Officer to help run it. According to ... it possesses. In fact, in the WCBJ’s July 21st, ...
(Date:7/30/2014)... 30, 2014 All the children at ... abandonment, rejection, abuse and exploitation tend to mar their ... hopelessness and dejection. Quality youth development has underpinnings in ... support boosts confidence and in the foreseeable future, would ... this light that the mere presence of Foundation members ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July 29, ... set the stage for harmful health habits, including eating disorders, ... from 1982 to 2012 also found a link between early ... a woman was when she started her first diet, the ... behaviors -- like vomiting or laxative misuse," said study researcher ...
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... nutrients in fruits and vegetables are vital to good health ... Once you,ve hit five servings of fruits and vegetables each ... new research review suggests. The human body may only ... and vegetables every day, limiting its ability to absorb important ...
Breaking Medicine News(10 mins):Health News:Global Catheters Market - Industry Size, Trends, Analysis, Growth, Players, Outlook and Forecast Research Report from 2014 to 2020: Grand View Research, Inc 2Health News:Global Catheters Market - Industry Size, Trends, Analysis, Growth, Players, Outlook and Forecast Research Report from 2014 to 2020: Grand View Research, Inc 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3Health News:The Edusei Foundation Donates Food and Assorted Items to the Fathers’ Home Care Ministries in Takoradi, Ghana 2Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 2Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 3
... (Nasdaq: SIAL ) is pleased to announce ... Corporate Controller effective April 13, 2009. Kanan (age 46) ... President-Strategy & Corporate Development. He will report to ... brings two decades of financial experience in assignments of ...
... Reovirus seeks out and destroys tumor cells, researchers say ... harmless human virus can target and kill breast cancer ... reovirus might be effective against cancer stem cells, because ... destroys regular cancer cells," Dr. Patrick Lee, a cancer ...
... Tau has been promoted to the position of Service ... at Baron Center, Inc (BCI). Dr. Tau is ... & forensic psychology. Dr. Tau is an expert in ... and has been extensively used as a workplace violence ...
... at Johns Hopkins have begun to tease out what there ... that leads so many patients to report depression after they ... 10 in Critical Care Medicine , the Hopkins researchers ... hospitalization among very sick ICU patients, including a high level ...
... dopamine agonists appear to curb compulsive acting out, study ... class of Parkinson,s disease drugs called dopamine agonists can ... gambling or hypersexuality, says a new study. , ... taking therapeutic doses of dopamine agonists, such as pramipexole ...
... Sinai faculty suggests that a gene associated with onset ... cases. The research, led by Dr. Giulio Maria Pasinetti, ... Professor of Psychiatry and Geriatrics and Adult Development at ... in the scientific journal, Archives of Neurology . ...
Cached Medicine News:Health News:Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller 2Health News:Harmless Virus May Be Deadly to Breast Cancer 2Health News:Manny Tau, Psy.D. Promoted to Service Area Leader for the Problematic Behaviors Service Area at Baron Center, Inc 2Health News:In the ICU, use of benzodiazepines, other factors may predict severity of post-stay depression 2Health News:Parkinson's Drugs Can Trigger Unhealthy Behaviors 2Health News:Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimer's disease 2
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... Pipettor is the #1 Pipettor for ... comfort, and reliability. Continuously adjustable. Features ... sub-micrometer. Easy interchangeable ejector buttons to ... Adjustable rapid pipet tip ejector with ...
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic ... greasing. Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... Precision (ul) ...
Medicine Products: